| Bengaluru, January 23, 2016: Biocon Ltd , Asia’s premier biopharmaceuticals company, announced Q3 FY16 results today.
Commenting on the quarterly performance and highlights, Chairperson and Managing Director, Kiran Mazumdar-Shaw stated : “Biocon’s four most advanced biosimilar and generic insulin programs, Insulin Glargine, Trastuzumab, Pegfilgrastim, and Adalimumab, continue to cross critical clinical milestones and are on track for regulatory filings in US & Europe in CY2016. These filings are likely to provide us an early mover advantage in an addressable US$30 Billion market. The progress made in our biosimilars and novel programs is reflected in the increase in R&D spends this quarter to Rs 68 crore. Excluding profit contribution from Syngene, Biocon’s net profit this quarter has increased by 28% y-o-y despite a 45% jump in R&D spends and a significant increase in tax. This reflects a marked improvement in the quality of our earnings led by better realizations from biosimilars and immunosuppressants in emerging markets. Syngene, our research services company, has delivered yet another strong quarter both in terms of revenues and profits .” Highlights: Q3FY16
Financial Highlights: Q3 FY16 In Rs crore, except growth numbers
Note: Executive Commentary R&D UPDATE The company recorded R&D spends of Rs 91 Cr in Q3FY16 at the gross level, an increase of 7% y-o-y, on account of the clinical advancement of several Biosimilars and Novel programs. At a P&L level, R&D spends rose 45% to Rs 68 Cr. Clinical Development of Biosimilars The Biocon-Mylan partnership includes six biosimilar programs (Trastuzumab, Pegfilgrastim, Adalimumab, Bevacizumab, Etanercept, and Filgrastim) and three insulin analog programs (Glargine, Lispro, and Aspart). Four of our most advanced programs, Insulin Glargine, Trastuzumab, Pegfilgrastim, and Adalimumab, continue to cross critical milestones in global Phase III clinical trials and are on track for regulatory filings in US & Europe in CY2016. These filings are likely to provide us an early mover advantage in an addressable US$30 billion market. The Bevacizumab global Phase I trial and the RoW-focused Phase III trial are advancing as per plan. Novel Programs Insulin Tregopil – The Oral Insulin The results of the global Phase I study conducted in the US has established the important role of Insulin Tregopil in post prandial glycemic control. It has demonstrated fast action of Insulin Tregopil with distinct properties compared to other prandial insulins like Aspart. Based on the positive results of these clinical studies Biocon plans to move to the next phase of clinical development on its own. Itolizumab- Novel anti-CD6 MAb We stay committed to developing this novel asset, a first-in-class anti-CD6 monoclonal antibody for a range of autoimmune conditions. During the quarter, in consultation with our global clinical advisory team, a Phase I study in normal healthy volunteers has been initiated in Australia. The study also aims to evaluate the pharmacokinetics of a sub-cutaneous route of administration of Itolizumab in comparison to intravenous route. SiRNA- based Therapeutics Biocon in collaboration with Quark Pharma, one of the leaders in the siRNA therapeutics, is developing QPI-1007, a novel siRNA asset, for a rare ophthalmic condition — Non-arteritic ischemic optic neuropathy (NAION). Patient enrollment for a global Phase III study for this program has commenced. OPERATIONAL PERFORMANCE The overall Sales at Rs 828 Cr registered a growth of 9% in Q3FY16. The Biopharmaceutical segment delivered sales of Rs 558 Cr, reporting a growth of 3% y-o-y. Within the segment, Biopharma grew 4% delivering Rs 454 Cr, while Branded Formulations sales stood at Rs 104 Cr for this quarter. Biopharmaceuticals Biopharma The overall Biopharma business continues to report a steady growth, with an increasing contribution from immunosuppressants and generic insulins in the emerging markets. The API development work for ANDA submissions has gained traction, putting us on track to file 20-25 dossiers over the next few years. The construction of our potent oral solid dosage formulations facility in Bengaluru supports our vertically integrated ANDA strategy. The process qualification of our Insulins facility in Malaysia has commenced, which puts us on track to file for approvals in FY17, as planned. We have made good progress in partnering and seeking approvals for biosimilar Trastuzumab in some of the major emerging markets. The introduction of Jalra (Vildagliptin) and Jalra M (Vildagliptin+ Metformin) for diabetes, in-licensed from Novartis Middle East by NeoBiocon strengthens our position as the fastest growing pharmaceutical company in UAE. Branded Formulations The Branded Formulations business continues to clock in over Rs 100 Cr each quarter, post rationalization of its product portfolio. The focus is on strengthening Biocon’s presence as a specialty pharma company by promoting its key brands across Metabolics, Onco-therapeutics, Immunology, Nephrology, Critical care and newly introduced Virology. All the divisions are also focusing on improving the profitability of this business. The Metabolics division continues to be the flagship segment of this business. It has held a steady 10% market share in the represented Insulins market. Biocon continues to be the largest Indian Insulins company. The newly introduced Virology division expanded its portfolio with the introduction of CIMIVIR-L™ (Ledipasvir+ Sofosbuvir) for Hepatitis-C Genotype 1 patients in India. It is estimated that nearly one lakh people die annually in India from HCV infections and co-morbidities. The Market Access division has also been successful in winning a few institutional tenders this quarter. Research Services – Syngene Our research services business through Syngene reported a strong revenue growth of 23% to Rs 270 Cr, this quarter, driven by a robust performance across three verticals- discovery services, dedicated centers, and development & manufacturing services. Syngene has also appointed Jonathan Hunt, as CEO designate, who brings in over two decades of expertise in the global biopharma sector and will lead the company towards its stated goal of achieving sales of US$ 250 million by FY18. Other Highlights: Awards & Recognitions Biocon’s commitment to operational excellence has been duly recognized through various awards received during this period, a few of them being:
Biocon also gained recognition as the ‘Best Employer Brand’ in Q3FY16 . It is the only Asian biopharma company to be included in the ‘Top 20 Global Biotech Employers 2015’ list by US-based ScienceCareers magazine. It has recognized Biocon as the most innovative leader in the industry, having loyal employees and being socially responsible. Encl.: Fact Sheet – Consolidated Income Statement and Balance Sheet (Indian GAAP) |
Home Spotlight Financial Results Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore; EBITDA Increases...
